medigraphic.com
Instituto Nacional de Salud Pública

2015, Number S2

<< Back Next >>

salud publica mex 2015; 57 (S2)

Antiretroviral purchasing and prescription practices in Mexico: constraints, challenges and opportunities

Chaumont C, Bautista-Arredondo S, Calva JJ, Bahena-González RI, Sánchez-Juárez GH, González de Araujo-Muriel A, Magis-Rodríguez C, Hernández-Ávila M

Language: English
References: 28
Page: 171-182
PDF size: 308.62 Kb.


ABSTRACT

Objective. This study examines the antiretroviral (ARV) market characteristics for drugs procured and prescribed to Mexico’s Social Protection System in Health beneficiaries between 2008 and 2013, and compares them with international data. Materials and methods. Procurement information from the National Center for the Prevention and the Control of HIV/AIDS was analyzed to estimate volumes and prices of key ARV. Annual costs were compared with data from the World Health Organization’s Global Price Reporting Mechanism for similar countries. Finally, regimens reported in the ARV Drug Management, Logistics and Surveillance System database were reviewed to identify prescription trends and model ARV expenditures until 2018. Results. Results show that the first-line ARV market is concentrated among a small number of patented treatments, in which prescription is clinically adequate, but which prices are higher than those paid by similar countries. The current set of legal and structural options available to policy makers to bring prices down is extremely limited. Conclusions. Different negotiation policies were not successful to decrease ARV high prices in the public health market. The closed list approach had a good impact on prescription quality but was ineffective in reduc-ing prices. The Coordinating Commission for Negotiating the Price of Medicines and other Health Supplies also failed to obtain adequate prices. To maximize purchase efficiency, policy makers should focus on finding long-term legal and political safeguards to counter the high prices imposed by pharmaceutical companies.


REFERENCES

  1. Centro Nacional para la Prevención y el Control del VIH/sida. El VIH/ sida en México en 2012. Mexico: Censida, 2012.

  2. Frenk J, González-Pier E, Gómez-Dantés O, Lezana MA, Knaul MF. Comprehensive reform to improve health system performance in Mexico. Lancet 2006;368:1524-1534 doi: 10.1016/S0140-6736(06)69564-0 pmid:17071286.

  3. Bonilla-Chacín ME, Aguilera N. UNICO Studies Series. The Mexican Social Protection System in Health. Washington, DC: The World Bank, 2013.

  4. Wirtz VJ, Santa-Ana-Téllez Y, Trout C, Kaplan A. Allocating scarce financial resources for HIV treatment: benchmarking prices of antiretroviral medicines in Latin America. Health Policy Plan 2012;27:638-648.

  5. Médecins Sans Frontières. Untangling the web of antiretroviral price reductions. 16th ed. Paris: MSF, 2013.

  6. Pan American Health Organization. Antiretroviral treatment in the spotlight: a public health analysis in Latin America and the Caribbean. Washington, DC: PAHO, 2013.

  7. Bendavid E, Leroux E, Bhattacharya J, Smith N, Miller G. The relation of price of antiretroviral drugs and foreign assistance with coverage of HIV treatment in Africa: retrospective study. BMJ 2010;341:c6218.

  8. Lucchini, S, Ciss B, Duran S, de Cenival M, Comiti C, Gaudry M, et al. Decrease in prices of antiretroviral drugs for developing countries: from political “philanthropy” to regulated markets. Paris: ANRS, 2003:169-211.

  9. Vasan A, Hoos D, Mukherjee J, Farmer P, Rosenfield A, Perriëns J. The pricing and procurement of antiretroviral drugs: an observational study of data from the Global Fund. Bull World Health Organ 2006;84(5):393-398.

  10. Wirtz V, Forsythe S, Valencia-Mendoza A, Bautista-Arredondo S. Factors influencing global antiretroviral procurement prices. BMC Public Health 2009;9(suppl 1):S6.

  11. Waning B, Kaplan W, King A, Lawrence D, Leufkens H, Fox M. Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases. Bull World Health Organ 2009;87:520-528.

  12. Adesina A, Wirtz VJ, Dratler S. Reforming antiretroviral price negotiations and public procurement: the Mexican experience. Health Policy Plan 2012;28(1):1-10.

  13. Gómez-Dantés O, Wirtz VJ, Reich M, Terrazasc P, Ortiz M. A new entity for the negotiation of public procurement prices for patented medicines in Mexico. Bull World Health Organ 2012;90:788-792.

  14. Centro Nacional para la prevención y el control del VIH/SIDA (Censida). Guía de manejo antiretroviral de las personas con VIH. 6th ed. Mexico: Censida, 2014.

  15. Neumann PJ. Evidence-based and value-based formulary guidelines. Health Affairs 2004;23(1):124-134.

  16. Moon S, Jambert E, Childs M, von Schoen-Angerer T. A win-win solution?: a critical analysis of tiered pricing to improve access to medicines in developing countries. Global Health 2011;7:39.

  17. Médecins Sans Frontières. Untangling the web of antiretroviral price reductions. 15th ed. Paris: MSF, 2012.

  18. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: WHO, 2013.

  19. Waning B, Kyle M, Diedrichsen E, Soucy L, Hochstadt J, Bärnighausen T, et al. Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets. Global Health 2010;6:9.

  20. Ministry of Health, Economic Analysis Unit. Costos de la terapia antirretroviral y su impacto en el financiamiento público. Mexico: 2011 [accessed on January 28, 2015]. Available at: http://www.censida.salud.gob. mx/congreso2011/Presentacion_CongresoVIH_Tabasco_v270711.pdf

  21. Comisión Nacional de Protección Social en Salud. Fideicomiso del Sistema de Protección Social en Salud. Auditoría Financiera y de Cumplimiento N° 11-0-12U00-02-0428 DS-056 [accessed on January 28, 2015]. Available at: http://www.asf.gob.mx/trans/informes/ir2011i/Grupos/Desarrollo_ Social/2011_0428_a.pdf.

  22. Secretaría de Salud, Subsecretaría de Prevención y Promoción de la Salud, Centro Nacional para la Prevención y el Control del VIH y el Sida. Sistema de Administración y Logística de ARV (SALVAR) [base de datos en Internet]. México: Censida, 2006 [accessed on March 1, 2014]. Available at: http://www.censida.salud.gob.mx/interior/atencion/bol_salvar.html

  23. Country and Londing groups by income. Data from the World Bank [accessed on January 28, 2015]. Available at: http://data.worldbank.org/ about/country-and-lending-groups

  24. Management Sciences for Health and World Health Organization. International drug price indicator guide. Medford, MA: MSH, 2012.

  25. Comisión Nacional de Protección Social en Salud, SALVAR. Quarterly Bulletins 1 to 21. from June 2008 to June 2013 [online documents] [accessed at november 14, 2015]. Available at: http://www.censida.salud.gob.mx/ interior/atencion/bol_salvar.html

  26. Centro Nacional para la prevención y el control del VIH/SIDA (Censida). Guía de manejo antiretroviral de las personas con VIH. 5th Ed. Mexico: Censida, 2012.

  27. Bautista-Arredondo S, Mane A, Bertozzi SM. Economic impact of antiretroviral therapy prescription decisions in the context of rapid scaling-up of access to treatment: lessons from Mexico. AIDS 2006;20(1):101-109. PubMed PMID:16327325.

  28. Hoen E, Berger J, Calmy A, Moon S. Driving a decade of change: HIV/ AIDS, patents and Access to medicines for all. J Int AIDS Soc 2011;14:15.




2020     |     www.medigraphic.com